People · Operator
Named in public records as an officer, director or promoter · active 2012–2024 · Biotechnology, Other Health Care, Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vascular Therapies Inc | — | Biotechnology | Series B | $89.2M | $471.9M | 2018 |
| Aseko Inc. | — | Other Health Care | Series B | $75.9M | $211.4M | 2018 |
| BioIQ, Inc. | — | Other | Series B | $59.6M | $232.6M | 2016 |
| Cell MDX, LLC | — | Other Health Care | Series B | $40.0M | $885.5M | 2012 |
| CuraSeal Inc. | — | Other | Seed | $7.1M | $53.7M | 2015 |
| Fidelis Animal Health Inc. | — | Pharmaceuticals | Series A | $6.1M | $6.1M | 2021 |
Andrew Midler at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Midler on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Wells | 2 | 3 |
| Patrick Cua | 2 | 2 |
| Somu Subramaniam | 1 | 17 |
| ROBERT CROCE | 1 | 7 |
| Evan Ng | 1 | 6 |
| Robert Fischell | 1 | 6 |
| Paul McCreadie | 1 | 6 |
| John McDermott | 1 | 5 |
| Daniel Ryan | 1 | 4 |
| Robert Flanagan | 1 | 4 |
| Brandon Cady | 1 | 4 |
| Robert Booth | 1 | 4 |
| Tim A Fischell | 1 | 4 |
| Todd Creech | 1 | 4 |
| Cheryl Pegus | 1 | 4 |
| Adam Fine | 1 | 4 |
| DAN RYAN | 1 | 4 |
| Phillip D. Torrence | 1 | 4 |
| GERALD DORROS | 1 | 3 |
| Randall Hawkins | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.